日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial

围手术期替雷利珠单抗联合乐伐替尼治疗复发风险高的可切除肝细胞癌:单臂 II 期试验

Chen, Lu; Zhai, Shujie; Liu, Yayue; Gong, Wenchen; Fang, Feng; Wu, Qiang; Cui, Yunlong; Zhang, Wei; Li, Huikai; Li, Yongmei; Hao, Jihui; Song, Tianqiang

Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma

整合多组学分析鉴定出胆管癌中一种免疫治疗脆弱且与预后相关的亚型

Chen, Lu; He, Yuchao; Su, Hong; Tian, Xiangdong; Liao, Haotian; Liu, Dongming; Zhao, Meng; Sun, Huichuan; Qi, Lisha; Cao, Manqing; Liu, Zhiyong; Guo, Lin; Li, Guangtao; Zhou, Chenhao; Luo, Yi; Chen, Liwei; Wu, Qiang; Cui, Yunlong; Li, Huikai; Zhu, Xiaolin; Fang, Feng; Zhang, Wei; Zhang, Shaojun; Song, Tianqiang; Guo, Hua

AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma

AdvanTIG-206:一项II期随机研究,比较奥西哌利单抗联合替雷利珠单抗和BAT1706(贝伐珠单抗生物类似药)与替雷利珠单抗联合BAT1706一线治疗肝细胞癌的疗效。

Ren, Zhenggang; Huang, Yao; Guo, Yabing; Hou, Ming-Mo; Wang, Wei; Kuang, Ming; Hao, Chunyi; Wang, Wentao; Zhang, Yanqiao; Song, Tianqiang; Dai, Chaoliu; Kuo, Hsing-Tao; Bao, Zinan; Zuo, Yunxia; Wang, Lei; Zhu, Fuxiang; Fan, Jia

High PMS2 Expression-Based Nomogram for Risk Stratification in Resected Hepatocellular Carcinoma: Application to Recurrence and Neoadjuvant Therapy Selection

基于高PMS2表达的列线图在切除肝细胞癌风险分层中的应用:在复发和新辅助治疗选择中的应用

Gong, Wenchen; Han, Ruyu; Sun, Liyu; Gao, Yingrui; Han, Zhiqiang; Wang, Yimeng; Xia, Yuren; Wei, Yukun; Song, Tianqiang; Chen, Lu; Tian, Xiangdong

Low SVEP1 in intrahepatic cholangiocarcinoma mediates phenotype switching-driven metastasis by Jag2/Notch1/Hes5

肝内胆管癌中低水平的SVEP1通过Jag2/Notch1/Hes5介导表型转换驱动的转移

Chen, Lu; Han, Zhiqiang; Tian, Xiangdong; Zhu, Kangwei; Gong, Wenchen; Liu, Yun; Wang, Yimeng; Xia, Yuren; Song, Peipei; Tang, Wei; Kokudo, Norihiro; Chen, Liwei; Luo, Yi; He, Yuchao; Song, Tianqiang; Guo, Hua

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)

中国肝癌诊疗指南(2024版)

Zhou, Jian; Sun, Huichuan; Wang, Zheng; Cong, Wenming; Zeng, Mengsu; Zhou, Weiping; Liu, Lianxin; Wen, Tianfu; Kuang, Ming; Zhang, Bixiang; Tao, Kaishan; Han, Guohong; Yan, Zhiping; Wang, Maoqiang; Liu, Ruibao; Guo, Jinhe; Zeng, Zhaochong; Liang, Ping; Ren, Zhenggang; Hou, Jinlin; Zhang, Yanqiao; Liu, Xiufeng; Pan, Hongming; Bi, Feng; Liang, Changhong; Chen, Min; Yan, Fuhua; Xu, Huixiong; Xie, Xiaoyan; Ju, Shenghong; Ji, Yuan; Yun, Jingping; Li, Zengshan; Bai, Xueli; Cai, Dingfang; Chen, Weixia; Chen, Yajin; Chen, Yongjun; Cheng, Wenwu; Cheng, Shuqun; Dai, Zhi; Dai, Chaoliu; Gao, Qiang; Guo, Rongping; Guo, Wengzhi; Guo, Yabing; Hua, Baojin; Huang, Xiaowu; Jiang, Hanyu; Jia, Weidong; Li, Qiu; Li, Tao; Li, Xiangcheng; Li, Xun; Li, Yaming; Li, Yexiong; Liang, Jun; Liang, Xiao; Ling, Changquan; Liu, Hui; Liu, Tianshu; Lu, Shichun; Lv, Guoyue; Mao, Yilei; Meng, Zhiqiang; Peng, Tao; Ren, Weixin; Shi, Guoming; Shi, Hongcheng; Shi, Ming; Song, Tianqiang; Tan, Guang; Wang, Jianhua; Wang, Kui; Wang, Lu; Wang, Wentao; Wang, Xiaoying; Wang, Zhiming; Xiang, Bangde; Xia, Jun; Xing, Baocai; Xu, Jianming; Xu, Jun; Yang, Jianyong; Yang, Xinrong; Yang, Yefa; Yang, Yunke; Yao, Xiaohong; Yin, Zhenyu; Yuan, Zhengang; Zeng, Yongyi; Zeng, Yong; Zhang, Boheng; Zhang, Leida; Zhang, Shuijun; Zhang, Ti; Zhang, Zhiwei; Zhao, Ming; Zhao, Yongfu; Zheng, Honggang; Zhou, Ledu; Zhu, Jiye; Zhu, Kangshun; Shi, Yinghong; Liu, Rong; Zhang, Lan; Xiao, Yongsheng; Yang, Chun; Wu, Zhifeng; Ding, Zhengbin; Zhu, Xiaodong; Tang, Zheng; Huang, Xiaoyong; Han, Hong; Wu, Hong; Chen, Minshan; Wang, Weilin; Li, Qiang; Cai, Jianqiang; Shen, Feng; Cai, Xiujun; Qin, Shukui; Teng, Gaojun; Fan, Jia

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

比较乐伐替尼与贝伐单抗联合免疫检查点抑制剂和介入三联疗法治疗中国晚期肝细胞癌的疗效:CLEAP 2302 研究

Pan, Zhaolong; Liu, Dongming; Cao, Junbo; Fu, Linlin; Zhang, Xihao; Zhu, Xiaodong; Pan, Yangxun; Liu, Jianwei; Han, Chuangye; Jin, Renan; Shen, Shunli; Zhang, Xiaoyun; Liu, Hongzhi; Yang, Xiaobo; Hu, Kuan; Shi, Xiaoyi; Wang, Dongxu; Zhao, Yang; Zhong, Jianhong; Xiang, Bangde; Gu, Shanzhi; Li, Tao; Zhang, Shuijun; Zhou, Ledu; Zhao, Haitao; Zeng, Yongyi; Wen, Tianfu; Kuang, Ming; Liang, Xiao; Peng, Tao; Wang, Kui; Xu, Li; Li, Huikai; Song, Tianqiang; Sun, Huichuan; Zhang, Wei

Individualized Prediction of Postoperative Survival in Gallbladder Cancer: A Nomogram Based on SEER Data and External Validation

基于SEER数据和外部验证的胆囊癌术后生存个体化预测列线图

Liu, Yayue; Zhu, Kangwei; Tian, Xindi; Chen, Ping; Xiong, Qingqing; Li, Guangtao; Ma, Xiaochen; Han, Ruyu; Sun, Liyu; Shen, Yijian; Zhu, Fengyi; Wang, Yimeng; Chen, Lu; Song, Tianqiang

Perioperative and precision strategies in resectable intrahepatic cholangiocarcinoma

可切除肝内胆管癌的围手术期和精准治疗策略

Chen, Lu; Han, Ruyu; Song, Tianqiang; Song, Peipei; Tang, Wei

Presence of symptoms predicts poor survival and correlates with COX-2 expression in resected intrahepatic cholangiocarcinoma patients.

症状的存在预示着较差的生存率,并且与肝内胆管癌切除患者的 COX-2 表达相关。

Yang Lu, Wang Yingying, Zheng Haijing, Pan Zhaolong, Xu Zezheng, Wang Yubo, Li Dongyang, Wang Yu, Yang Bo, Zang Fenglin, Zhang Qin, Cao Guangtai, Li Huikai, Cui Yunlong, Wu Qiang, Song Tianqiang, Li Qiang, Zhang Wei